Alx Oncology Holdings (ALXO) Non-Current Debt (2019 - 2026)
Alx Oncology Holdings (ALXO) posted Non-Current Debt of $3.3 million for Q1 2026, down 27.29% sequentially from $4.5 million in Q4 2025, and down 59.97% YoY from $8.2 million in Q1 2025.
Alx Oncology Holdings (ALXO) Non-Current Debt (2019 - 2026) Analysis & Trends
Alx Oncology Holdings has reported Non-Current Debt for 7 years, with the latest figure at $3.3 million in Q1 2026.
- Quarterly Non-Current Debt fell 59.97% year-over-year to $3.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.3 million (down 59.97% YoY) and the FY2025 annual result came in at $4.5 million, down 52.14% from the prior year.
- Non-Current Debt fell to $3.3 million in Q1 2026 per ALXO's latest filing, from $4.5 million in the prior quarter.
- Over five years, Non-Current Debt peaked at $9.8 million in Q3 2024 and troughed at $3.3 million in Q1 2026.
- A 5-year average of $8.2 million and a median of $9.5 million in 2023 frame the typical range for Non-Current Debt.
- The sharpest annual moves came in 2024 and 2026: Non-Current Debt gained 2.72% in 2024, then tumbled 59.97% in 2026.
- Over 5 years, Non-Current Debt stood at $9.4 million in 2022, then climbed by 2.66% to $9.6 million in 2023, then decreased by 1.76% to $9.5 million in 2024, then tumbled by 52.14% to $4.5 million in 2025, then fell by 27.29% to $3.3 million in 2026.
- According to Business Quant data, Non-Current Debt over the past three periods registered $3.3 million, $4.5 million, and $5.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Alx Oncology Holdings | 270.90 Mn | 270.90 Mn | - | 9.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.71 Mn |
| Mar 31, 2026 | 3.30 Mn |
| Dec 31, 2025 | 4.53 Mn |
| Sep 30, 2025 | 5.76 Mn |
| Jun 30, 2025 | 7.00 Mn |
| Mar 31, 2025 | 8.23 Mn |
| Dec 31, 2024 | 9.47 Mn |
| Sep 30, 2024 | 9.84 Mn |
| Jun 30, 2024 | 9.77 Mn |
| Mar 31, 2024 | 9.70 Mn |
| Dec 31, 2023 | 9.64 Mn |
| Sep 30, 2023 | 9.58 Mn |
| Jun 30, 2023 | 9.51 Mn |
| Mar 31, 2023 | 9.45 Mn |
| Dec 31, 2022 | 9.39 Mn |
| Sep 30, 2020 | 3.19 Mn |
| Jun 30, 2020 | 3.93 Mn |
| Dec 31, 2019 | 5.42 Mn |